Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of r
Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in andr...
Neuroendocrine prostate cancer samples were retrieved from the SU2C cohort (samples annotated with neuroendocrine features) and from Beltran et al.69. The total number of SPOP-mutant and TMPRSS2-ERG tumors was determined based on the individual studies’ clinical annotations and integrated with ...
Neuroendocrine Prostate Cancer - ScienceDirectJ.M. MosqueraH. BeltranM.A. RubinPathobiology of Human Disease
Here, we introduce a versatile in vivo platform to interrogate neuroendocrine lineage transformation throughout prostate cancer progression. Transplanted mouse prostate organoids with human-relevant driver mutations (Rb1−/−; Trp53−/−; cMyc+ or Pten−/−; Trp53−/−; cMyc+) ...
Prostate cancer (PC) is an epithelial malignancy occurring in the prostate. PC ranks second in incidence among all male malignancies globally by the latest
Findings In this cohort study including tissue samples from 634 patients with metastatic prostate cancer, distinct molecular patterns associated with luminal and basal subtypes were identified; in addition, enrichment of small cell/neuroendocrine prostate cancer samples were noted in the basal tumors. The...
the tumors progress to CRPC by increasing cell cycle genes and eventually dedifferentiate toAR-negative disease with or without neuroendocrine features (neuroendocrine prostate cancer (NEPC)) (Fig.1e). Notably, the transcriptional changes correlated well with the protein level changes in an independent...
Although resistance develops in response to androgen receptor-targeted therapy in advanced prostate cancer, the underlying mechanisms remain unclear. The protein ZMYND8 is now shown to bind FOXM1 and the SWI–SNF complex, promoting the onset of neuroendocrine prostate cancer, which can thus be abroga...
Prostate Cancer In subject area:Pharmacology, Toxicology and Pharmaceutical Science Aggressive variant prostate cancer (AVPC) is a clinically defined tumor with neuroendocrine or small-cell differentiation, visceral metastases, low prostate-specific antigen, androgen receptor insensitivity, and poor response ...